Printer Friendly

SARALYNN MANDEL JOINS CELL GENESYS AS DIRECTOR OF INTELLECTUAL PROPERTY

 SARALYNN MANDEL JOINS CELL GENESYS AS
 DIRECTOR OF INTELLECTUAL PROPERTY
 FOSTER CITY, Calif., Aug. 4 /PRNewswire/ -- Cell Genesys Inc. announced today that SaraLynn Mandel has joined the company in the newly established position of director of intellectual property and senior patent counsel. Mandel, who has more than nine years of biotechnology patent law experience, will be responsible for directing Cell Genesys' worldwide patent activities.
 "Cell Genesys' core technologies, including gene targeting, offer a wide range of novel product development activities and an opportunity to establish a strong proprietary position," said Stephen A. Sherwin, M.D., president and chief executive officer. "We are fortunate that we have been able to attract a leading biotechnology patent counsel with the stature of SaraLynn Mandel."
 During the past nine years, Mandel has been in the private practice of biotechnology patent law, most recently at the offices of Sheldon & Mak in Los Angeles. She was senior biotechnology patent attorney at the firm and represented both biomedical industry and academic clients.
 Mandel received her bachelor of arts degree in biology from the University of California at Los Angeles and a master of science degree from the University of Washington in Seattle. She received a doctor of law degree from the University of Puget Sound School of Law in Tacoma, Wash. Mandel is a registered patent attorney with the U.S. Patent and Trademark Office and is a member of both the State Bar of California and the Washington State Bar.
 Cell Genesys Inc. is a privately held biotechnology company which is a pioneer in the application of gene targeting technology to the development of human therapeutic health care products. The company is using gene targeting and related technologies to develop universal cell transplant products, human therapeutic protein products and human monoclonal antibody products.
 -0- 8/4/92
 /CONTACT: Stephen A. Sherwin of Cell Genesys, 415-358-9600 ext. 212/ CO: Cell Genesys Inc. ST: California IN: MTC SU: PER


JL-DG -- SF002 -- 6681 08/04/92 13:00 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 4, 1992
Words:330
Previous Article:HERSHEY FOODS CORPORATION ANNOUNCES DIVIDEND INCREASE
Next Article:GENERAL MOTORS REPORTS SALES
Topics:


Related Articles
DR. KRISZTINA ZSEBO JOINS CELL GENESYS AS DIRECTOR OF RESEARCH FOR CELLULAR THERAPY
CELL GENESYS ANNOUNCES KEY PRODUCT DEVELOPMENT HIRES
CELL GENESYS PROMOTES KRISZTINA ZSEBO, PH.D., TO VICE PRESIDENT OF PRODUCT DEVELOPMENT
CELL GENESYS ADDS TWO KEY PRODUCT DEVELOPMENT DIRECTORS
CELL GENESYS NAMES EXECUTIVE TEAM FOR NEW SUBSIDIARY, ABGENIX
CELL GENESYS ANNOUNCES EXECUTIVE PROMOTIONS
Cell Genesys and Somatix Agree to Merge
Abgenix and Japan Tobacco Cross License Human Monoclonal Antibody Technology With GenPharm
Dr. John Lipani Joins the Abgenix Management Team
Abgenix Board Appoints Kurt Leutzinger as Chief Financial Officer

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters